A randomized, double-blind trial in China concluded that folic acid supplementation significantly reduced the risk of first stroke in patients with high blood pressure. The trial was conducted from May 2008 to August 2013 and 20,702 adults with hypertension without history of stroke or myocardial infarction (MI) were randomly assigned to receive daily treatment with a single-pill combination containing enalapril (10 mg) and folic acid (0.8 mg; n = 10,348), or a tablet containing enalapril alone (10 mg; n = 10,354). During a median treatment duration of 4.5 years, there was significant reductions among participants in the enalapril-folic acid group in the risk of first stroke (2.7 vs 3.4 percent), ischemic stroke (2.2 percent vs 2.8 percent) and composite cardiovascular events (cardiovascular death, MI and stroke; 3.1 percent vs 3.9 percent). The beneficial effect appeared to be more pronounced in participants with lower folate levels. There was no significant difference between groups in the risk of hemorrhagic stroke, MI, or all-cause death, or in the frequencies of adverse events. Source: http://jama.jamanetwork.com/中国一项随机，双盲试验得出结论：补充叶酸显著降低高血压患者第一次中风的风险。该试验在2008年5月至2013年8月间进行，20702名患有高血压而无中风或心肌梗塞史的成人被随机分配接受每日一片含依那普利（10毫克）和叶酸（0.8毫克; N = 10348）的复方制剂，或一片单药含依那普利（10毫克; N = 10354）。在平均4.5年的治疗期间，依那普利叶酸组患者的首次中风（2.7％ 相对于 3.4％），缺血性中风（2.2％相对于 2.8％）和复合心血管事件（心血管病死亡，心肌梗塞和中风; 3.1％相对于 3.9％）的风险均显著降低。对叶酸水平较低者的有益效果似乎更显着。两组间出血性中风，心肌梗塞或全因死亡以及不良反应的频率没有显著差异。来源： http://jama.jamanetwork.com/
This website uses cookies.